Molbio Diagnostics Ltd (MOLBIO) — Board Meeting | 1 September 2026

· BSE 🟡 Notable Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
Board to approve unaudited Q1 FY27 financial results
💡 Investor Takeaway
The filing signals upcoming financial disclosure that may influence valuation and trading activity.

Molbio Diagnostics announced a board meeting on September 5, 2026 to approve unaudited financial results for the quarter ended June 30, 2026, with trading restrictions in place until 48 hours after approval.

📄 View Original Announcement (PDF)

About Molbio Diagnostics Ltd (MOLBIO)

Healthcare · Healthcare · Listed on BSE

Market Cap: ₹16,255.48 Cr

View full MOLBIO stock details →

📡 Get AI alerts when MOLBIO files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track MOLBIO — Free

📊 More MOLBIO filings

See all MOLBIO filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when MOLBIO files new disclosures

Track MOLBIO filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track MOLBIO — Free

Free account · 2 AI queries/day